Cited 18 times in
Therapeutic Outcome of Epstein-Barr Virus Positive T/NK Cell Lymphoma in the Upper Aerodigestive Tract
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김귀언 | - |
dc.contributor.author | 민유홍 | - |
dc.date.accessioned | 2016-05-16T10:59:00Z | - |
dc.date.available | 2016-05-16T10:59:00Z | - |
dc.date.issued | 2002 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/143531 | - |
dc.description.abstract | Expression of the natural killer (NK) cell antigen CD56 is uncommon in malignant lymphoma, but when it is, it is almost exclusively of the non-B cell lineage and show a preference for the nasal and nasopharyngeal region. T/NK cell lymphoma is known to be aggressive and refractory to treatment. It is highly associated with the Epstein-Barr Virus (EBV), but clinical investigations are rarely reported, that is until recently. We report here, on the clinical features and therapeutic outcomes of patients with T/NK cell lymphomas and its association with EBV. We reviewed fifty-four cases with peripheral T cell lymphomas in the upper aerodigestive tract between Jan. 1987 and Aug. 1998 from the Severance Hospital, Yonsei University College of Medicine. The diagnosis of T/NK cell lymphoma was made according to the expression of the NK cell markers, CD56 antigen and cytoplasmic CD3 ε, in tumor specimens, by immunohistochemistry. Epstein-Barr early region (EBER) RNA was detected using in situ hybridization on paraffin-embedded sections. Among the 54 cases with malignant lymphomas occurring in the upper aerodigestive tract, 20 had T/NK cell lymphoma (37%). The primary sites of T/NK cell lymphomas were the nasal cavity, 12 cases (60%), the tonsils, 4 cases (20%), the nasopharynx, 2 cases (10%), and the oropharynx, 2 case (10%). There were no differences between the features, at diagnosis or therapeutic modalities for patients with T/NK cell lymphoma and non-T/NK cell lymphoma. The complete remission rate of T/NK cell lymphomas was lower than non-T/NK cell lymphomas (65% vs 85%, p=0.02). The overall survival of T/NK cell lymphomas was 13 months (1-74 month), which was significantly lower than non-T/NK cell lymphomas [60.6% with a median follow up of 22 months (1-101 month, p=0.02)]. Disease free survival of T/NK cell lymphomas was 22 months (4-66 month), significantly lower than non-T/NK cell lymphomas [73.8% with a median follow up of 22 months (2-95 month), p=0.04]. The overall survival rates for T/NK cell lymphomas were significantly lower than for EBV positive non-T/NK cell lymphomas (p=0.018). EBER RNA was detected in the paraffin-embedded tissue sections of all T/NK cell lymphomas, compared to only 17.6% (6 of 34 cases) for non-T/NK cell lymphomas. In conclusion, as patients with T/NK cell lymphomas showed poor clinical outcomes, and a high association with EBV positivity, clinical trials with more investigational therapeutic strategies, and further research into the relationship of EBV infection with pathogenesis of T/NK cell lymphoma is warranted. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 175~182 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Digestive System Neoplasms/therapy* | - |
dc.subject.MESH | Digestive System Neoplasms/virology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Herpesvirus 4, Human/isolation & purification | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Killer Cells, Natural* | - |
dc.subject.MESH | Lymphoma/therapy* | - |
dc.subject.MESH | Lymphoma/virology | - |
dc.subject.MESH | Lymphoma, T-Cell/therapy* | - |
dc.subject.MESH | Lymphoma, T-Cell/virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Respiratory Tract Neoplasms/therapy* | - |
dc.subject.MESH | Respiratory Tract Neoplasms/virology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Therapeutic Outcome of Epstein-Barr Virus Positive T/NK Cell Lymphoma in the Upper Aerodigestive Tract | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | Jee Sook Hahn | - |
dc.contributor.googleauthor | Seung Tae Lee | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.contributor.googleauthor | Yun Woong Ko | - |
dc.contributor.googleauthor | Woo Ick Yang | - |
dc.contributor.googleauthor | Gwi Eon Kim | - |
dc.identifier.doi | 10.3349/ymj.2002.43.2.175 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00321 | - |
dc.contributor.localId | A01407 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 11971211 | - |
dc.subject.keyword | CD 56+ | - |
dc.subject.keyword | T/NK cell lymphoma | - |
dc.subject.keyword | Epstein-Barr virus | - |
dc.contributor.alternativeName | Kim, Gwi Eon | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Kim, Gwi Eon | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 43 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 175 | - |
dc.citation.endPage | 182 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.43(2) : 175-182, 2002 | - |
dc.identifier.rimsid | 38232 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.